Optimization of pharmacotherapy of patients with prostate adenoma with hormonal and metabolic disordes: correction of vitamin D deficiency with "Aquadetrim"

The article notes that modern studies demonstrate an epidemiological and pathogenetic role of systemic hormonal and metabolic disorders in men with prostate adenoma (PA), so it is obvious that a pharmacotherapeutic correction of these disorders can increase the efficacy of the traditional therapy of the diseas

Correction of morphofunctional disorders with asialoerythropoietin and selective inhibitor of arginase II KUD975 in cases of ischemic kidney damage in the experiment

Acute kidney injury (AKI), which is based on ischemic-reperfusion damage, is a widespread life-threatening condition and remains a serious public health problem with a high mortality rate among patients. Pharmacological preconditioning and the use of endothelioprotectors are promising areas in this field, therefore the purpose of this study was to analyze the nephroprotective properties of asialoerythropoietin and selective inhibitor of arginase II KUD975 in ischemic kidney damage in the experimen

Clinical and experimental rationale for antioxidant therapy of chronic bacterial prostatitis

Aim of study: To improve the results of the pharmacotherapy of CBP by a comprehensive assessment of oxidative disorders in the prostate gland in a clinical and experimental study to provide evidence for antioxidant suppor

Nutritional supplementation of the pharmacotherapy of prostate diseases

Nutritional supplementation is an integral part of modern pharmacotherapeutic strategies for prostate diseases with different levels of evidence for specific nutrient

Zinc metabolism in healthy men and in patients with chronic bacterial prostatitis

The purpose of this study is to research the features and possible correlations of zinc metabolism disorders at systemic (in blood) and local (in prostatic fluid) levels in healthy men and patients with chronic bacterial prostatitis (CBP

THE CORRECTION OF ENDOTHELIAL DYSFUNCTION WITH THE HELP OF DISTANT ISCHEMIC AND PHARMACOLOGICAL PRECONDITIONING WITH THERMAL LOCAL ASPHYXIA OF KIDNEY

This article contains the results of research of the endothelial dysfunction arising during the modeling of thermal local asphyxia of kidney and possibilities of their correction by distant ischemic and pharmacological preconditioning. The modeling of thermal local asphyxia of kidney is characterized by the disturbance of microcirculation and expression of eNOS in the kidney tissue. The usage of distant ischemic preconditioning and phosphodiesterase inhibitors type 5 sildenafil and tadalafil leads to pronounced correction of microcirculation dysfunction and activity of eNOS. During the modeling of thermal local asphyxia of kidney against endothelium dysfunction caused by ADMA-like L-NAME induced deficiency of nitric oxide more pronounced dysfunction of microcirculation and activity of eNOS are observed. The usage of distant ischemic and pharmacological preconditioning with the help of phosphodiesterase inhibitors type 5 in this type of pathology led to pronounced correction of microcirculation dysfunction and activity of eNOS. The injection of glibenclamide blocker of ATP – dependent K+ channels during the correction of the disturbance caused by the modeling of thermal local asphyxia of kidney with the help of distant ischemic and pharmacological preconditioning leads to the decrease of its efficiency.Disclosure: The study did not have sponsorship. The authors have declared no conflicts of interest

LOWER URINARY TRACT SYMPTOMS CAUSED BY BENIGN PROSTATIC HYPERPLASIA: RESULTS OF TREATMENT DEPENDING ON ANDROGEN STATUS

Objective is to study and compare the effect of different regimes of drug therapy on prostate volume and residual urine volume in men with lower urinary tract symptoms caused by benign prostatic hyperplasia (LUTS/BPH), depending on their androgenic status.Materials and methods. Carried out a comparative analysis of the effect on the prostate volume and the residual urine volume of different pharmacotherapy regimes (monotherapy α -blocker (n = 40), inhibitor of 5α-reductase (n = 35), herbal medicine (n = 30), combination therapy, α -blocker and inhibitor of 5α-reductase (n = 40)) in men with LUTS/BPH with unspecified androgen status, as well as combination therapy of α -blocker, 5α-reductase inhibitor and testosterone undecanoate (n = 42) in men with LUTS/BPH and androgen deficiency within 24 months. The total number of patients was 187 (mean age 65.3 ± 3.2 yrs).Results. In routine practice, without taking into account the androgenic status of patients, the most pronounced reduction in prostate volume compared to the initial (by 26.6 %) was achieved through 24 months of monotherapy with 5α-reductase inhibitor (p <0.05). Against the background of monotherapy α -blocker for 24 months there was, on the contrary, an increase in the average volume of the prostate gland by 8.2 % (p <0.05), and in the group of monotherapy with herbal medicine – by 1.1 %. The average of residual urine volume against the background of monotherapy α -blocker decreased in 24 months by 35.4 %, in groups of monotherapy with inhibitor of 5α-reductase by 56.2 % and with herbal preparation – by 8.6 % (p <0.05).Combined therapy with the use of testosterone undecanoate in men with LUTS/BPH and androgen deficiency had a significantly more positive effect on prostate volume and residual urine volume compared to standard combination therapy, excluding androgen status patients (p <0.05).Conclusion. The additional positive effect of androgen replacement therapy on prostate volume and residual urine volume can significantly reduce the manifestations of infravesical obstruction

Correction of morphofunctional disorders with asialoerythropoietin and selective inhibitor of arginase II KUD975 in cases of ischemic kidney damage in the experiment

Acute kidney injury (AKI), which is based on ischemic-reperfusion damage, is a widespread life-threatening condition and remains a serious public health problem with a high mortality rate among patients. Pharmacological preconditioning and the use of endothelioprotectors are promising areas in this field, therefore the purpose of this study was to analyze the nephroprotective properties of asialoerythropoietin and selective inhibitor of arginase II KUD975 in ischemic kidney damage in the experimen

Pharmacological preconditioning of resveratrol in ischemic / reherfusion injury: the role of nitric oxide

The article presents the results of studies of the effect of distant preconditioning by creating short-term limb ischemia and pharmacologic preconditioning of resveratrol on the size of myocardial necrosis and the level of troponin I in serum after ischemia-reperfusion. Established a comparable protective effect as distant and pharmacological preconditioning. Possible mechanisms of the protective effect of pharmacological preconditioning during ischemia/reperfusion. Preconditioning of the heart by resveratrol provides cardioprotection, as evidenced by the reduction in the size of the area of myocardial necrosis. Cardioprotection resveratrol was completely abolished as N-nitro-L-arginine methyl ester (L-NAME), and aminoguanidine (AG), which show that resveratrol provides cardioprotection type of ischemic preconditioning by nitric oxide synthase (NOS)

THE STUDY OF RENOPROTECTIVE PROPERTIES OF ERYTROPOETIN DERIVATIVES ON THE KIDNEY ISCHEMIA-REPERFUSION MODEL

Aim. The research was designed to study the renoprotective properties of erythropoietin derivatives on the kidney ischemiareperfusion experimental model.Materials and methods. The renoprotective properties of asialo erythropoietin (0.4 μg/kg and 2.4 μg/kg 30 minutes before the induction of ischemia) and carbamylated darbepoetin (50 μg/kg 24 hours before the ischemic stimulus) were studied in comparison with erythropoietin and darbepoetin in a series of experiments on male Wistar rats on a 40-minute bilateral model of renal ischemia-reperfusion. The renoprotective properties were evaluated by the results of biochemical markers of acute kidney injury, the dynamics of glomerular filtration rate and fractional sodium excretion, as well as the severity of microcirculatory disorders.Results. It was found that the prophylactic use of asialo erythropoietin (dose-dependent) and carbamylated darbepoetin leads to a decrease in the serum concentration of markers of acute renal damage, an increase in the glomerular filtration rate, a decrease in fractional sodium excretion, and a decrease in microcirculatory disorders.Conclusion. Asialo erythropoietin and carbamylated darbepoetin have the pronounced renoprotective properties and are the promising agents for the prevention and treatment of acute kidney injury